KPV Category 2 status: current compounding access explained

FDA removed KPV from Category 2 in April 2026. That did not put KPV on the 503A bulks list.

Update, September 14, 2026: FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026, and voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

TL;DR

• KPV's regulatory status changed in April 2026. FDA gave notice on April 15 and removed KPV from Category 2 on April 22, 2026.
• Removal isn't authorization. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list.
• At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What is KPV Category 2 status?

KPV sat on the FDA's Section 503A (in plain English: the FDA rule covering custom-mixed pharmacy medicines) Category 2 list for years, which blocked pharmacies from preparing it. On April 22, 2026, the FDA removed KPV and 11 other peptides from Category 2 (FDA, 2026). KPV is a tripeptide (in plain English: a chain of three amino acids) made of lysine, proline, and valine. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone, or alpha-MSH (in plain English: a natural hormone that helps control inflammation).

Is KPV legal to compound in 2026?

Not yet, at least not through a standard 503A pharmacy. Removal from Category 2 lifts a prohibition — it does not add KPV to the approved bulk substances list. That step is FDA's decision, after advice from the Pharmacy Compounding Advisory Committee, or PCAC (in plain English: the FDA's expert panel that advises on what pharmacies may compound). Clearing Category 2 opened one door; KPV hasn't opened the second one yet.

When does the FDA review KPV?

The PCAC met July 23-24, 2026. KPV-related bulk substances were on the July 23 agenda alongside BPC-157, TB-500, and MOTS-c. Semax, Epitalon, and Emideltide (DSIP) followed on July 24. Seven peptides total were reviewed across both days for possible addition to the Section 503A Bulks List. The committee voted to recommend adding KPV to the list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What is KPV used for?

Researchers have nominated KPV for wound healing and inflammatory conditions, the use the PCAC reviewed in July 2026. KPV entered mouse colon cells through the PepT1 transporter (in plain English: a doorway on gut cells that pulls in small fragments, like a mail slot for letters). It reduced colitis severity there (Dalmasso et al., Gastroenterology, 2008). Earlier work isolated the anti-inflammatory activity of this alpha-MSH fragment (Getting et al., 2003). This is mouse data, not a confirmed human benefit.

The Halftime POV

We'd rather explain the two-checkpoint distinction than let a "removed from Category 2" headline imply KPV is cleared. It isn't. We'll update this page when FDA makes a final decision.

Related reading:

• KPV: who asks about it
• PCAC July 2026 meeting: what's on the agenda
• 12 peptides removed from FDA restriction in 2026
• Category 2 and patient risk, explained

FAQ

Q: What is KPV Category 2 status? A: KPV was on the FDA's Category 2 list, which flagged it as a bulk substance that compounding pharmacies could not legally prepare under Section 503A. FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list.

Q: Is KPV legal to compound in 2026? A: Removal from Category 2 did not add KPV to the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision, and KPV is not on the list.

Q: When does the FDA review KPV? A: The Pharmacy Compounding Advisory Committee discussed KPV-related bulk drug substances on July 23, 2026, alongside BPC-157, TB-500, and MOTS-c. The committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

Q: What is KPV used for? A: KPV's nominated use before the Pharmacy Compounding Advisory Committee was wound healing and inflammatory conditions. Mouse studies found it reduced colitis severity after entering colon cells through the PepT1 transporter, but this is animal data, not a confirmed human benefit (Dalmasso et al., Gastroenterology, 2008).

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

Sources

• July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA
• Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — FDA (2026)
• Dalmasso G et al., KPV reduces colitis severity via the PepT1 transporter, Gastroenterology (2008)
• Getting SJ et al., anti-inflammatory activity of the alpha-MSH C-terminal fragment KPV (2003)